Patents by Inventor Mike Welch

Mike Welch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cold storage charging system and method
    Patent number: 11820248
    Abstract: Systems and methods for temperature control for an energy source of a material handling vehicle. The system includes a battery management system in communication with the energy source that can also be in communication with a charger. The system further includes a counterweight case that supports the energy source, and a plurality of resistive heating elements positioned along one or more surfaces of the counterweight case.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: November 21, 2023
    Assignee: The Raymond Corporation
    Inventors: John Bryant Kirk, Mike Welch, Tanvir Reza Tanim
  • Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
    Patent number: 11807651
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: November 7, 2023
    Assignees: Loxo Oncology Inc., Array BioPharma Inc.
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE
    Publication number: 20210380609
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 9, 2021
    Inventors: Charles Todd EARY, Stacey SPENCER, Zack CRANE, Katelyn CHANDO, Sylvie ASSELIN, Weidong LIU, Mike WELCH, Adam COOK, Gabrielle R. KOLAKOWSKI, Andrew T. METCALF, David A. MORENO, Tony P. TANG
  • Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile
    Patent number: 11098064
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: August 24, 2021
    Assignees: Loxo Oncology, Inc., Array BioPharma, Inc.
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • Cold Storage Charging System and Method
    Publication number: 20210159555
    Abstract: Systems and methods for temperature control for an energy source of a material handling vehicle. The system includes a battery management system in communication with the energy source that can also be in communication with a charger. The system further includes a counterweight case that supports the energy source, and a plurality of resistive heating elements positioned along one or more surfaces of the counterweight case.
    Type: Application
    Filed: February 5, 2021
    Publication date: May 27, 2021
    Inventors: John Bryant Kirk, Mike Welch, Tanvir Reza Tanim
  • Cold storage charging system and method
    Patent number: 10923775
    Abstract: Systems and methods for temperature control for an energy source of a material handling vehicle. The system includes a battery management system in communication with the energy source that can also be in communication with a charger. The system further includes a counterweight case that supports the energy source, and a plurality of resistive heating elements positioned along one or more surfaces of the counterweight case.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: February 16, 2021
    Assignee: The Raymond Corporation
    Inventors: John Bryant Kirk, Mike Welch, Tanvir Reza Tanim
  • PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE
    Publication number: 20200308194
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: Charles Todd EARY, Stacey SPENCER, Zack CRANE, Katelyn CHANDO, Sylvie ASSELIN, Weidong LIU, Mike WELCH, Adam COOK, Gabrielle R. KOLAKOWSKI, Andrew T. METCALF, David A. MORENO, Tony P. TANG
  • Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
    Patent number: 10745419
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 18, 2020
    Assignees: Loxo Oncology Inc., Array Biopharma Inc.
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • PROCESS FOR THE PREPARATION OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE
    Publication number: 20190106438
    Abstract: In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.
    Type: Application
    Filed: October 10, 2018
    Publication date: April 11, 2019
    Inventors: Charles Todd Eary, Stacey Spencer, Zack Crane, Katelyn Chando, Sylvie Asselin, Weidong Liu, Mike Welch, Adam Cook, Gabrielle R. Kolakowski, Andrew T. Metcalf, David A. Moreno, Tony P. Tang
  • COLD STORAGE CHARGING SYSTEM AND METHOD
    Publication number: 20180053972
    Abstract: Systems and methods for temperature control for an energy source of a material handling vehicle. The system includes a battery management system in communication with the energy source that can also be in communication with a charger. The system further includes a counterweight case that supports the energy source, and a plurality of resistive heating elements positioned along one or more surfaces of the counterweight case.
    Type: Application
    Filed: August 16, 2017
    Publication date: February 22, 2018
    Inventors: John Bryant KIRK, Mike Welch, Tanvir Reza Tanim
  • Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
    Patent number: 9409886
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: August 9, 2016
    Assignees: ARRAY BIOPHARMA INC., GENENTECH, INC.
    Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
  • PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20160152601
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: November 21, 2013
    Publication date: June 2, 2016
    Applicants: Array BioPharma Inc., Genentech, Inc.
    Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
  • PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20140080829
    Abstract: The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: November 21, 2013
    Publication date: March 20, 2014
    Applicants: Genentech, Inc., Array BioPharma Inc.
    Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
  • Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
    Patent number: 8618097
    Abstract: The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: December 31, 2013
    Assignees: Array Biopharma, Inc., Genentech, Inc.
    Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
  • PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
    Publication number: 20110015204
    Abstract: The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: July 3, 2008
    Publication date: January 20, 2011
    Applicants: Array BioPharma, Inc., Genentech, Inc.
    Inventors: Josef Bencsik, James F. Blake, James M. Graham, Martin F. Hentemann, Nicholas C. Kallan, Ian S. Mitchell, Stephen T. Schlachter, Keith L. Spencer, Dengming Xiao, Rui Xu, Mike Welch, Jun Liang, Brian S. Safina
  • Imidazopyrazines as Raf inhibitor compounds
    Patent number: 7566716
    Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: July 28, 2009
    Assignee: Array Biopharma Inc.
    Inventors: Ellen Laird, George Topalov, Joseph P. Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse
  • RAF INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20090176809
    Abstract: Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: December 31, 2008
    Publication date: July 9, 2009
    Inventors: Ellen Laird, Joseph P. Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse, Alan Olivero, George Topalov
  • RAF inhibitor compounds and methods
    Patent number: 7491829
    Abstract: Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: February 17, 2009
    Assignees: Array Biopharma Inc., Genentech, Inc.
    Inventors: Ellen Laird, Joseph P. Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse, Alan Olivero, George Topalov
  • Raf inhibitor compounds and methods of use thereof
    Publication number: 20060281751
    Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: May 18, 2006
    Publication date: December 14, 2006
    Inventors: Ellen Laird, George Topalov, Joseph Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse
  • RAF inhibitor compounds and methods
    Publication number: 20060189627
    Abstract: Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Application
    Filed: February 2, 2006
    Publication date: August 24, 2006
    Inventors: Ellen Laird, Joseph Lyssikatos, Mike Welch, Jonas Grina, Josh Hansen, Brad Newhouse, Alan Olivero, George Topalov